Suche Bilder Maps Play YouTube News Gmail Drive Mehr »
Einstellungen | Anmelden

IIB Development Lead

Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast ...

Business Wire (press release) - ‎vor 14 Stunden‎
... in the US market place. The company will also take this opportunity to review in further detail the most recent proof of concept AURION study data, and the Phase IIb AURA-LV study design. ... The event is intended for investors, sell-side analysts ...

WHO'S NEWS: Two join team at Colliers, Fred Smith joins NGKF as vice chairman

Real Estate Weekly - ‎vor 18 Stunden‎
Jadoo previously served as a lead leasing consultant for Aimco, where she managed the leasing of a 266-unit residential community, and as a sales agent for Coldwell Banker, where she sold residential properties in Bergen County.

Progress, setbacks in understanding tau

BioWorld Online - ‎vor 12 Stunden‎
Amyloid-targeting antibodies can lead to amyloid-related imaging abnormality (ARIA), a collective term for vasogenic edema (ARIA-E) and microhemorrhage (ARIA-H).

Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the ...

PR Newswire (press release) - ‎28.07.2016‎
TEL AVIV, Israel, July 28, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver ...

Cowen & Company Downgrades Zafgen Inc to Market Perform

Trade Calls - ‎vor 7 Stunden‎
The Company's lead product candidate Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications including severe obesity in two rare diseases Prader-Willi syndrome (PWS) and hypothalamic injury ...

TxCell: Financial Information for the 2nd Quarter of 2016

Business Wire (press release) - ‎27.07.2016‎
The CATS29 study is a phase IIb, placebo-controlled clinical trial with TxCell's lead drug-candidate Ovasave® in patients with moderate to severe Crohn's disease refractory to existing treatments, which represents a major unmet medical need.

Immupharma (LON:IMM) New Price Targets

FTSE News - ‎vor 8 Stunden‎
The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases.

Moleculin Biotech Inc (NASDAQ:MBRX): Proceed With Caution

Market Exclusive - ‎27.07.2016‎
IND submissions cost around $600K, and since the company is applying for a special protocol assessment which will allow it to use a phase IIb as a pivotal trial) it could be months before it's even allowed to start its own development of Annamycin ...

Why Empery Asset Management Reported Big Evoke Pharma Inc Position?

Consumer Eagle - ‎vor 2 Stunden‎
The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has ... According to Zacks Investment Research, “Evoke Pharma, Inc. is a specialty ...
Echtzeit-Berichte

Biotech Movers: Gilead Sciences, Inc. (NASDAQ:GILD) and CARDIOME ...

Market Exclusive - ‎26.07.2016‎
The other, Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. It generated circa $20 million revenues from the two during 2015, but spent ... The company also picked up an approval during the ...

Postponing Nasdaq IPO, Poxel raises €26.5M to move diabetes drug into PhIII

FierceBiotech - ‎19.07.2016‎
With the Phase IIb data potentially setting imeglimin on a path that leads to it coming to market in Japan in 2020, investors have stepped up with the €26.5 million Poxel needs to realize this vision.

Evoke Pharma Inc: Intracoastal Capital Opened Big New Position

Press Telegraph - ‎27.07.2016‎
The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has ... According to Zacks Investment Research, “Evoke Pharma, Inc. is a specialty ...
Echtzeit-Berichte

Zafgen (ZFGN) Shares are Down -55.84%

Trade Calls - ‎25.07.2016‎
The Companys lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury ...
Echtzeit-Berichte

Home Biotech Stocks Zafgen, Inc. | $ZFGN Stock | Shares Crash Down On ...

TickerTV News (press release) - ‎20.07.2016‎
Zafgen, Inc. (ZFGN), a biopharmaceutical company yesterday announced that they will be suspending their development of beloranib and start to refocus its resources to its second generation MetAP2 inhibitor ZGN-1061.

Moleculin Announces Successful Engineering Run for Production of Annamycin

Marketwired (press release) - ‎19.07.2016‎
HOUSTON, TX --(Marketwired - July 19, 2016) - Moleculin Biotech, Inc., ( NASDAQ : MBRX) ("Moleculin" or the "Company"), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are ...

Aurinia Pharmaceuticals Inc (AUPH) Updated Price Targets

FTSE News - ‎25.07.2016‎
It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Frigate Ventures Lp Just Disclosed New Evoke Pharma Inc Position

Consumer Eagle - ‎26.07.2016‎
The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company ... According to Zacks Investment Research, “Evoke Pharma, Inc. is a specialty ...
Echtzeit-Berichte

Stocks in the Spotlight: American International (AIG), Stone Energy (SGY ...

iStreetWire - ‎27.07.2016‎
Stone Energy Corporation, an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and operation of oil and gas properties in the Gulf of Mexico. ... The company's lead product candidate, NeuVax ...

ImmuPharma PLC (LON:IMM) Issued With 'Buy' Rating At Northland Capital

FTSE News - ‎21.07.2016‎
The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases.

Opexa Therapeutics Inc. (OPXA) Downgraded by Zacks Investment Research to ...

Community Financial News - ‎20.07.2016‎
The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide ... The Company is in preclinical development for type one diabetes. “ OPXA has been the subject of a number ...
 -